Portfolio Projects Portfolio Projects Figure 11 Figure 11 AC drilling commenced at the Balla Balla Gold Project1 in the Pilbara, Western Australia. The ~6,000 m program is testing priority target zones of structural complexity and splay faults proximal to the Sholl Shear Zone and is progressing well.Two three-week field campaigns were completed at the Tibooburra and John Bull Gold Projects in northern New South Wales.Results from the Tibooburra field program which focused on the Clone prospect inclu ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperforming the market [3] Value Score - The Value Score identifies attractive stocks using ratios like P/E, PEG, and Price/Sales, focusing on stocks that are undervalued [3] Growth Score - The Growth Score assesses a company's future prospects by analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing factors like one-week price changes and monthly earnings estimate changes [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [6] Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in stock selection [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with a 4 (Sell) or 5 (Strong Sell) rating, even with high Style Scores, are less favorable due to declining earnings forecasts [10] Company Spotlight: Novo Nordisk - Novo Nordisk, based in Denmark, is a leading global healthcare company specializing in diabetes care and other therapeutic areas [11] - The company holds a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating moderate potential [11] - Novo Nordisk's Value Style Score is B, supported by a forward P/E ratio of 16.11, making it attractive for value investors [12] - The Zacks Consensus Estimate for fiscal 2025 is $3.80 per share, with recent upward revisions from analysts [12]

Core Viewpoint - Novo Resources Corp. has launched an updated corporate presentation to provide investors with insights into its growth strategy and key projects in its Australian gold exploration portfolio [1][2][3]. Company Overview - Novo Resources is an Australian-based gold explorer listed on ASX and TSX, focusing on discovering standalone gold projects with over 1 million ounces (Moz) development potential [5]. - The company holds a significant land package of approximately 5,500 square kilometers in the Pilbara region of Western Australia and an additional 22 square kilometers at the Belltopper project in Victoria, Australia [5]. Key Projects - The Egina Gold Camp is a primary project area where De Grey Mining is forming a joint venture (JV) at the Becher Project, committing A$25 million over four years for a 50% interest [6]. - Novo is also advancing exploration south of Becher in the Egina Gold Camp and has a lithium joint venture with SQM in the Pilbara, providing exposure to battery metals [7]. - Recently, Novo added the TechGen John Bull Gold Project and the Manhattan Tibooburra Gold Project to its portfolio, both of which show potential for significant discoveries and align with the company's strategy of identifying projects with over 1 Moz Au potential [8]. Investment Strategy - Novo has a disciplined program in place to identify value-accretive opportunities that will enhance shareholder value [9].

On Friday, The Centers for Medicare & Medicaid Services (CMS) did not finalize a provision to cover obesity drugs like Eli Lilly's (LLY) and Novo Nordisk’s (NVO) popular injections, Zepbound and Wegovy, respectively, under its Part D prescription drug coverage. In other words, Medicare will not pay for the cost of these expensive weight-loss medicines.At present, Medicare does not cover Zepbound and Wegovy if they are solely prescribed for weight loss. However, CMS may consider these proposals at a later da ...

Core Viewpoint - Novo Nordisk announced significant changes in its Executive Management team, effective April 3, 2025, following the departure of Camilla Sylvest after 28 years with the company [1]. Group 1: Executive Management Changes - Camilla Sylvest, after a 28-year career with Novo Nordisk, including seven years as executive vice president of Commercial Strategy & Corporate Affairs, has decided to leave the company [1]. - Ludovic Helfgott, previously executive vice president of Rare Disease, will take on the role of executive vice president for Product & Portfolio Strategy, overseeing commercial strategy, medical affairs, and business development across all therapy areas [1]. - Thilde Hummel Bøgebjerg has been promoted to executive vice president of Quality, IT & Environmental Affairs, having spent 18 years with Novo Nordisk in various leadership roles [2]. - Tania Sabroe, currently executive vice president of People & Organisation, will also assume responsibility for Global Communication [3]. Group 2: Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focusing on chronic diseases, particularly diabetes [4]. - The company employs approximately 76,300 people across 80 countries and markets its products in around 170 countries [4]. - Novo Nordisk's B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange [4].

HIGHLIGHTS Recent exploration by Novo at the Clone prospect included detailed structural, lithological and regolith mapping, pXRF and < 80# mesh soil sampling, and rock chip sampling. Novo rock chip sampling returned peak results of 89.6 g/t Au and 41.9 g/t Au from mullock dump samples associated with historical workings, and 31.4 g/t Au and 10.4 g/t Au from quartz vein outcrop over 700 m of strike, supporting previous high grade drill results. Soil sampling defined a ~ 600 m long and up to 250 m wide coher ...

Core Viewpoint - The divergence in stock performance between Eli Lilly and Novo Nordisk since the start of 2025 highlights the impact of product pipelines and market perceptions in the biotech sector, with Eli Lilly showing a YTD increase of 6.97% while Novo Nordisk has seen a decline of 18.87% [1][2]. Company Performance - Eli Lilly's stock is currently trading at a forward price-to-earnings (PE) ratio of 36.26, while Novo Nordisk's forward PE is significantly lower at 17.23, indicating a more attractive valuation for Novo Nordisk [4]. - The trailing PE ratios for Eli Lilly and Novo Nordisk are 69.29 and 21.45, respectively, further emphasizing the valuation gap [4]. Market Outlook - Analysts from Bank of America have expressed concerns about Novo Nordisk potentially missing first-quarter sales expectations, which could lead to a 2% reduction in full-year sales guidance, projecting a sales growth range of 14% to 22% for the year [6]. - Despite the concerns, Bank of America maintains that Novo Nordisk's guidance remains competitive against Eli Lilly, with a revised price target of $131, down from $155, still suggesting an upside of 87% to 70% [7]. Analyst Sentiment - Currently, 10 analysts are tracking Novo Nordisk, with an equal split of five ratings as 'Buy' and five as 'Hold'. The average price target is $110.36, indicating a potential upside of 58.13% from current prices [8][11]. - Novo Nordisk is noted as one of the stocks with the largest projected upside according to Wall Street analysts [8].

Core Viewpoint - Novo Nordisk defends the disappointing trial results of its obesity drug candidate CagriSema, asserting its potential as an important weight loss treatment despite underwhelming performance in clinical trials [1][2]. Company Summary - CEO Lars Fruergaard Jørgensen acknowledged the negative impact on share price following two late-stage trials that showed lower-than-expected weight reduction results, yet expressed confidence in CagriSema's weight loss profile [2][5]. - CagriSema, a combination of cagrilintide and semaglutide, demonstrated a weight loss of 15.7% over 68 weeks in patients with type 2 diabetes, compared to 3.1% with placebo, which fell short of the high-teens percentage previously forecast [3][4]. - A prior trial indicated a 22.7% weight loss in obese patients without type 2 diabetes, also below the expected 25% [4][7]. - The company's stock has declined over 50% from its 2024 highs due to investor disappointment regarding the drug's performance compared to existing treatments like Wegovy and Eli Lilly's Zepbound [5]. Industry Summary - Shareholders have called for clearer trial designs and targets to mitigate drastic share price fluctuations, with the CEO acknowledging the need for better communication regarding trial designs [6]. - The weight-loss industry is experiencing skepticism regarding the differentiation of obesity drugs, as noted by BofA Global Research, which has become more cautious following CagriSema's results [8]. - Analysts emphasize the necessity for a diverse range of treatments to address obesity and related health risks, highlighting the significant market opportunity for various products catering to different patient needs [9].

Company Overview - Novo Resources Corp. is an Australian-based gold explorer listed on the ASX and TSX, focused on discovering standalone gold projects with over 1 million ounces (Moz) development potential [4] - The company has a significant land package covering approximately 5,500 square kilometers in the Pilbara region of Western Australia, along with the 22 square kilometer Belltopper project in Victoria, Australia [4] Recent Developments - As of March 31, 2025, Novo has changed its shareholder registry services provider from MUFG Pension & Market Services to Automic Pty Ltd, enhancing shareholder management through Automic's secure online investor portal [1][2] - Novo has formed a lithium joint venture with SQM in the Pilbara, providing shareholders exposure to battery metals [6] Key Projects - The Egina Gold Camp is a key project area where De Grey Mining is farming-in to form a joint venture at the Becher Project, with an exploration expenditure of A$25 million over four years for a 50% interest [5] - Novo is advancing gold exploration south of Becher in the Egina Gold Camp, part of the Croydon joint venture (Novo 70%: Creasy Group 30%) [5] - Recently, Novo has added the TechGen John Bull Gold Project and the Manhattan Tibooburra Gold Project to its portfolio, both demonstrating significant discovery potential and aligning with the company's strategy [7] Exploration Targets - Novo has defined an exploration target with a tonnage range of 1.5 million tonnes (Mt) to 2.1 Mt, a grade range of 6.6 grams per tonne (g/t) to 8.4 g/t gold, and an ounces range from 320,000 ounces (koz) to 570 koz [9]

Core Viewpoint - Novo Nordisk's stock declined over 2% following a downgrade in price target by Morgan Stanley, reflecting concerns over its competitive position in the obesity medication market [1][2]. Group 1: Price Target and Recommendations - Morgan Stanley's analyst Thibault Boutherin reduced Novo Nordisk's price target from 700 Danish kroner ($101.11) to 600 kroner ($86.67) while maintaining an equalweight (hold) recommendation [2]. - The downgrade is attributed to concerns regarding the subscription rates for Novo Nordisk's Wegovy compared to Eli Lilly's Zepbound [2]. Group 2: Market Competition - Eli Lilly's Zepbound commands 59% of overall weekly prescriptions for weight-loss medications, leaving Novo Nordisk with 41% [3]. - The disparity is even more pronounced for starting doses, with Zepbound at 68% and Wegovy at 32% [3]. - Novo Nordisk faces significant competition not only from Eli Lilly but also from various other companies developing obesity products, necessitating a proactive approach to maintain market success [4]. Group 3: Future Guidance - Due to the competitive pressures, it is anticipated that Novo Nordisk may lower its full-year 2025 guidance, potentially announced during its first-quarter earnings release [3].